How to use this page
I wrote this one for the caregiver. It covers the cream on the shelf, the itch that takes the night, school, and the visit.
Psoriasis in children is recognized, and published guidance covers this age group. That guidance is what I read before writing what follows.
Your child will want more of the talking as they grow. Hand that over in pieces rather than all at once.
Community ideas are labeled because they vary by person. They are options, not promises about how another person will respond.
Psoriasis in children is covered by guidelines
A child with psoriasis is not an edge case. Care for this age group is written down.
I read the joint guideline the American Academy of Dermatology and the National Psoriasis Foundation publish for psoriasis in children. It covers topical treatment, phototherapy and systemic treatment.
I checked what NICE assesses: the skin, the nails, high-impact sites, the impact on daily life, and any joint concerns. Your child’s day counts inside that.
So you can ask a dermatologist what the pediatric guidance says for a child your child’s age. That is a fair question to put in the room.
The steroid cream worry
People I have heard from hold the tube and hesitate. Knowing what it is, and who sets the limits, takes some of that weight off.
A topical steroid is an anti-inflammatory medicine you put on the skin. I read the American Academy of Dermatology page on them: they cut redness, swelling, scaling and itch.
They come in strengths from very mild to extremely strong. A strong product on thin skin such as the face carries skin-thinning, spider-vein and stretch-mark risk.
The National Psoriasis Foundation records the same potency range. It advises checking with a clinician rather than carrying on with a topical steroid without review.
So strength, body site and how long a course runs are the prescriber’s call. Ask for those limits in writing, and read them back at the next visit.
The topical steroids guide and the side effects guide below cover the product detail and the reasons to call.
Sources for the facts above: Evidence Evidence Evidence
Ask your care teamLived experience - varies by person
Scratching, itch, and lost sleep
Itch is often the part that wears a family down. It takes the night as well as the day.
I read the NIAMS symptom list, which includes poor sleep quality. It also lists patches that itch or burn, and dry, cracked skin that itches or bleeds.
I read a 2023 study of 200 adults with psoriasis, and worse itching lined up with worse sleep on every measure checked. That study enrolled no children.
The American Academy of Dermatology records that treating the psoriasis itself is the most effective way to relieve itch. So a bad run of nights belongs at the visit, not just in the bedroom.
Count the broken nights in a week and say that number out loud. The itch and sleep guide below covers this in more depth.
School, PE, swimming, and the contagious question
The question your child will hear most is whether it is catching. One short answer settles it.
I read the National Psoriasis Foundation page, which records psoriasis as an immune-mediated disease. An overactive immune system speeds up skin-cell growth, and plaques are the visible sign.
So a plaque is your child’s own immune system at work. It is not an infection that moves to a classmate in a pool or a changing room.
I read the StopBullying.gov advice for adults: agree in advance on who a child goes to and what happens next. Name that adult before there is a problem.
Do not ask your child to explain psoriasis to a class unless they want to. In the US, a formal disability-accommodation plan may apply when a student meets the legal rules for one. School rules differ, and this is general orientation rather than legal advice.
For PE, swimming and changing rooms, ask the dermatologist what to do about chlorine, showers and anything that stings a plaque.
Flares that follow an infection
A sore throat is sometimes followed by a crop of small spots. That pattern is recorded, not imagined.
I checked the American Academy of Dermatology trigger list, which names infection. It names strep throat, an earache and bronchitis, and reports such a flare 2 to 6 weeks later.
NIAMS records that guttate psoriasis outbreaks are often triggered by an upper respiratory infection such as strep throat. The joint pediatric guideline records the same link in children.
Both patient sources also say triggers differ from person to person. So a flare after an illness is worth a call, and a flare with no clear cause is not a failure.
The guide on whether psoriasis clears or flares, linked below, covers the wider pattern.
Mood in children and teens
Skin is visible and school is public. Watch the mood as closely as the plaques.
I read the joint pediatric guideline, which advises screening children who have psoriasis for related conditions. It names depression and anxiety among them.
NIAMS records that psoriasis carries risk for mental-health concerns including low self-esteem, anxiety and depression.
A 2010 UK study of family-doctor records found higher rates of noted depression and anxiety among people with psoriasis. That is a pattern across a group, not a forecast for your child.
If your child’s mood worries you, say so at the visit and ask who on the team handles that part. The anxiety and depression guide below covers what support can look like.
Sources for the facts above: Evidence Evidence Evidence
Ask your care teamLived experience - varies by person
Keeping a record for the pediatric dermatologist
A short record beats memory. It keeps a visit from turning into a guess about last month.
I looked at the National Psoriasis Foundation tracker page: tracking symptoms and triggers over time can help find a pattern. It says the record can be shared with a health care provider.
It suggests describing symptoms clearly and noting changes in severity and in the areas affected. The tracking guide below covers photos and what to write down.
The American Academy of Pediatrics advises raising a child’s part in health decisions as they develop, alongside parental permission. Let your child add their own line to the record.
Bring to your next visit
You can use these as written or change the words. Saving keeps a question on this device.
Which exact topical steroid product and strength have you prescribed for my child, and which body areas is it for?
Saving keeps this on your device and needs JavaScript, which is off in this browser.My child’s itching breaks their sleep most nights. What would you change about their treatment for that?
Saving keeps this on your device and needs JavaScript, which is off in this browser.My child had strep throat and small spots followed. Should we call you when that happens again?
Saving keeps this on your device and needs JavaScript, which is off in this browser.My child’s mood has changed since this started. Who on your team should we talk to about that?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the American Academy of Dermatology (Menter A, Cordoro KM, Davis DMR, et al.)Guideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to the author relationships disclosed for the guideline, not to the journal itself.
What this source supports
Supports that the American Academy of Dermatology and the National Psoriasis Foundation share one guideline for psoriasis in children. Supports that it covers topical, light and systemic treatment in that age group. Supports the reported link between guttate psoriasis in a child and strep throat. Supports checking a child who has psoriasis for other health problems. It names low mood and anxiety. It also names extra weight.
What it does not support
It does not judge one child. It names no product, no strength and no course length. It gives no figure for how many children get better. It is US guidance. It sets no coverage rule.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute for Health and Care ExcellenceGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports psoriasis assessment across skin, nails, high-impact sites, life impact and joint concerns; same-day specialist assessment for generalised pustular psoriasis or erythroderma; and a treatment map that includes topical, phototherapy and systemic options.
What it does not support
It is UK guidance and does not diagnose a reader, create a US treatment sequence, determine personal urgency from a description, or establish current US labeling or coverage.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that topical corticosteroids reduce redness, swelling, scaling and itch, and slow skin-cell growth. They come in strengths from very mild to extremely strong and are typically applied twice daily. Strong products on thin skin such as the face carry skin-thinning, spider-vein and stretch-mark risk. Most people see results with short twice-daily use, and no improvement after four to six weeks is a signal to return to the prescriber.
What it does not support
The page does not display its own separate revision date; the date recorded here matches the same AAD psoriasis treatment section’s dated overview page checked the same day. It does not name potency classes by number, give a percentage of people who improve, or set a maximum course length.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization provides patient education, but its editorial and funding independence for this page was not independently reviewed.
What this source supports
Supports that topical steroids range from super-potent to least potent, and that guidance advises not using one for longer than three weeks without checking with a clinician. Side effects include skin thinning, pigment change, easy bruising, stretch marks, redness and dilated blood vessels. Systemic absorption is a risk with widespread, prolonged or occluded use, and abruptly stopping a topical steroid can cause a psoriasis flare.
What it does not support
It does not name which specific product falls in which potency class, quantify how often a side effect occurs, or set a course length for any specific product or body site.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that poor sleep quality is a listed symptom of psoriasis. Also lists patches of thick, red, scaly skin that itch or burn, and dry, cracked skin that itches or bleeds. Supports that psoriasis carries risk for mental-health concerns including low self-esteem, anxiety, and depression. Supports that managing common triggers, such as stress and skin injuries, can help keep symptoms under control. Supports, by subtype, that guttate psoriasis outbreaks are often triggered by an upper respiratory infection such as strep throat. Also supports that pustular psoriasis symptoms can be triggered by medications, infections, stress, or certain chemicals. Also supports that erythrodermic psoriasis can be triggered by a bad sunburn or certain medications including corticosteroids. Also supports, by subtype, that inverse psoriasis appears as smooth patches of inflamed skin in skin folds. It names the armpits, the groin, and under the breasts as those folds. It records that rubbing and sweating can make inverse psoriasis worse.
What it does not support
Does not give a percentage of patients affected. Does not measure how much sleep is lost. Does not establish that treating the skin fixes the sleep problem for any one person. Its trigger information is organized by psoriasis subtype, not as one general list for plaque psoriasis specifically. It counts nothing for inverse psoriasis either. It gives no share of people affected in a fold or genital site, and it names no treatment for one.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Scientific Reports (Zaky MS, Elgamal EA, Mohamed DH, Abd Al Maksoud AA, Elsaie ML)Observational study · Clinical research, tier 2Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Government research-funding acknowledgment only (Egypt STDF/EKB); the authors state no competing interests.
What this source supports
Supports that in a study of 200 people with psoriasis, 16% had poor sleep quality overall. That rose to 50% among people with severe psoriasis and 25% with moderate psoriasis, against 11.8% with mild psoriasis. Supports that people with worse itching had much worse sleep on every measure checked. Supports that higher disease-severity scores lined up with worse sleep quality, shorter sleep, and more sleep disturbance. Both links were strong enough that chance alone is an unlikely explanation.
What it does not support
A single-hospital study in Egypt. It had no comparison group and mostly mild-to-moderate cases. Sleep was measured with a questionnaire, not a sleep lab. It shows a pattern across a group, not that itching causes poor sleep. It does not predict any one person’s sleep.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports treating the psoriasis itself as the most effective way to relieve itch. Supports moisturizing instead of scratching, especially after washing. Supports warm water, and showers of about 5 minutes or baths of about 15 minutes. Supports a cool, damp washcloth on itchy skin. Supports an anti-itch product with menthol or camphor as ingredients that tend to work well.
What it does not support
Does not quantify how much itch a given step relieves. Does not say an anti-itch product replaces psoriasis treatment.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization publishes patient education, but the editorial and funding independence of this page was not separately reviewed.
What this source supports
Supports that psoriasis is an immune-mediated disease. It causes inflammation in the body. Raised plaques and scale on the skin are the visible sign. Supports that an overactive immune system speeds up skin-cell growth. Skin cells normally take about a month to grow and shed. With psoriasis they do so in three or four days. Supports that psoriasis is a chronic, long-term disease with no cure.
What it does not support
Does not predict whether one person will clear, stay the same, or flare. Does not give a share of people who reach a period with little or no psoriasis, or how long such a period lasts. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- StopBullying.gov, U.S. Department of Health and Human ServicesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports listening to a child, identifying trusted adults, working with the child on a response and following through with school support.
What it does not support
It is general U.S. bullying guidance, not a Vitiligo-specific school protocol, a legal entitlement or a guarantee that a school response will stop harm.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that stress can trigger a psoriasis flare. Supports that skin injury - a cut, scrape, sunburn, tattoo, piercing, bug bite, or shaving nick - can trigger a flare near or at that spot. Typically this appears about 10 to 14 days after the injury. Supports that an infection such as strep throat, an earache, or bronchitis can trigger a flare, reported 2 to 6 weeks later. Supports that starting a medication - including lithium, antimalarial drugs, strong corticosteroids, or some blood pressure drugs - can trigger a flare about 2 to 3 weeks after starting it. Supports that cold, dry weather (such as winter or fall) can worsen flares, and that sunburn or spending time in air conditioning can also worsen them. Supports that smoking, or spending time around secondhand smoke, is a reported trigger. Supports that drinking daily, or more than two drinks on several days a week, can make psoriasis treatment have little or no effect. Supports that triggers differ from person to person.
What it does not support
Does not cite a specific study for its trigger list or timing windows, and does not state how many patients experience each trigger. This page displays no revision date; the date recorded here matches the same AAD psoriasis disease microsite's treatment-and-diagnosis page, checked the same day. Does not establish that avoiding a listed trigger will prevent a flare for any one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Archives of Dermatology (Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM)Observational study · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Funding and conflict notes were not checked beyond the published record. So the status here is set to not established.
What this source supports
Supports that one study used a UK family-doctor database. It tracked more than 145,000 people with psoriasis. It also tracked a much larger group with no psoriasis. Supports a higher rate of noted depression in the psoriasis group. Supports a higher rate of noted anxiety. Supports a higher rate of noted self-harm risk. Supports that the rise in depression showed up in mild psoriasis. Supports that the rise was larger in severe psoriasis.
What it does not support
Does not show that psoriasis causes any of this. Does not judge or predict one person. It counts only what a doctor wrote down. So it misses what was never raised in a visit. It covers one database and one span of years. It does not describe US care today.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that tracking symptoms and common triggers over time can help a person figure out their own specific triggers. Supports naming stress, alcohol, and diet as examples of common triggers to watch for. Supports naming discolored skin patches and itching as psoriasis symptoms, and joint swelling and fatigue as psoriatic arthritis symptoms, to watch for. Supports using a worksheet to record daily symptoms and their severity, and sharing that worksheet with a health care provider.
What it does not support
Does not give a percentage or timeline for how much tracking changes any one outcome. Does not name every possible trigger - stress, alcohol, and diet are examples, not a complete list. Does not measure whether tracking itself helps or burdens a given person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing a symptom tracker, kept on paper or on a phone, to share with a doctor at an appointment. Supports clearly describing symptoms and noting changes in severity and affected areas as part of preparing for a visit.
What it does not support
Does not mention photographing skin changes specifically. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of Pediatrics Committee on BioethicsGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports increasing a child or adolescent’s participation in health decisions in keeping with development, alongside parental permission and professional responsibility.
What it does not support
It is general pediatric ethics guidance, not a SteadySkin minimum-age policy, a jurisdiction-specific consent opinion or evidence for any Vitiligo treatment.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.